摘要
鳞状细胞癌是头颈部最常见的恶性肿瘤,严重威胁患者生命。继传统的手术治疗和放、化疗后,免疫治疗为患者带来了新的希望。临床上应用程序性死亡配体-1(programmed death-1 ligand 1,PD-L1)免疫检查点抑制剂单药或联合靶向、化疗方案可以改善患者生存率,因此被多项国内或国际指南推荐。肿瘤免疫微环境中三级淋巴结构(tertiary lymphoid structure,TLS)、高肿瘤突变负荷(tumor mutation burden,TMB)、OX40激活性抗体以及淋巴细胞活化基因-3(lymphocyte-activation gene 3,LAG-3)蛋白的表达,以及它们与肿瘤良好预后之间的相关性,意味着它们可能成为新的预测指标,同时对人乳头状瘤病毒(human papilloma virus,HPV)在头颈部鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)中的探索也有望为临床医生提供新的治疗思路。
Squamous cell carcinoma is the most common malignant tumor in head and neck,which is a serious threat to the lives of the patients.In addition to the traditional surgical treatment,radiotherapy and chemotherapy,immunotherapy has brought new hope to the patients.The clinical application of programmed death-1 ligand 1(PD-L1)immune checkpoint inhibitor can improve the survival rate of the patients.The latest studies have shown that the tertiary lymphoid structure(TLS),high tumor mutation burden(TMB),expression of OX40 activating antibody and lymphocyte-activation gene-3(LAG-3)protein in tumor immune microenvironment are correlated with good prognosis of head and neck squamous cell carcinoma(HNSCC),indicating that these indicators can be used for prediction the prognosis of HNSCC patients.Meanwhile,the human papilloma virus(HPV)positive HNSCC may be associated with better prognosis of patients,the roles of HPV in HNSCC are worth further studying.
作者
杨惠茹
鲁海珍
YANG Hui-ru;LU Hai-zhen(National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《中国肿瘤》
CAS
CSCD
北大核心
2022年第5期387-393,共7页
China Cancer
基金
中国癌症基金会北京希望马拉松专项基金(LC2021A16)。
